Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Neoplasm Metastasis 5Colorectal Neoplasms 4Solid Tumor 3Stomach Neoplasms 2Melanoma 2Endometrial Neoplasms 2Turcot syndrome 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Rectal Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Metastatic Solid Tumors 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1Extensive Stage Small Cell Lung Cancer 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colonic Neoplasms 1Breast Neoplasms 1Advanced Solid Tumors 1Adenocarcinoma 1

Interventions

tislelizumab 1Paclitaxel 1Injections 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Extensive Stage Small Cell Lung Cancer × tislelizumab × Clear all
NCT06897579 2026-04-28

Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Terminated
40 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡